RALEIGH, N.C., Dec. 18, 2015 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) provided an update on its development pipeline and announced plans for an R&D day in early 2016. BDSI has initiated its multi-center, randomized, double-blind, placebo controlled study to assess the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with painful diabetic neuropathy. The study design incorporates significant learnings from two previously conducted studies and involves tightened and additional inclusion criteria to improve assay sensitivity, reduce bias, and ensure compliance with enrollment criteria. BDSI expects the first patient to be enrolled shortly with study recruitment expected to be completed before the end of 2016.